Stock Markets March 4, 2026

FDA Operations Chief to Step Down; Melanie Keller to Fill Post on April 6

Agency veteran with three decades of HHS experience will assume operational leadership as wider public health leadership shifts continue

By Sofia Navarro
FDA Operations Chief to Step Down; Melanie Keller to Fill Post on April 6

Barclay Butler, the FDA’s deputy commissioner for operations and chief operating officer, will retire from federal service in the coming months and will remain as an adviser with the title COO emeritus until his departure. Melanie Keller, a 30-year Department of Health and Human Services veteran and Butler’s deputy, will assume his duties on April 6. The appointments occur amid broader personnel changes across federal public health agencies.

Key Points

  • Barclay Butler will retire from federal service and will remain as an adviser titled COO emeritus until his departure - sectors affected: federal health administration and regulatory agencies.
  • Melanie Keller, a 30-year HHS veteran and former executive officer at the FDAs Center for Drug Evaluation and Research, will assume Butlers operational roles on April 6 - sectors affected: healthcare regulation and pharmaceutical oversight.
  • Melissa Shea will replace Keller as principal deputy associate commissioner for operations and deputy COO; she has over 24 years of program management experience and prior senior roles at the Defense Health Agency - sectors affected: defense health and government healthcare programs.

Barclay Butler, who has spent about a year serving as the U.S. Food and Drug Administrations deputy commissioner for operations and chief operating officer, will retire from federal service in the coming months, according to an internal email reviewed by Reuters. The email said Butler will continue to serve as an adviser under the title COO emeritus until he leaves.

FDA Commissioner Marty Makary informed staff that Melanie Keller, who has been Butlers deputy, will step into his operational roles starting on April 6. Keller brings 30 years of experience in senior posts across the Department of Health and Human Services to the position.

Within Kellers federal tenure, she served from 2010 to 2017 as the executive officer at the FDAs Center for Drug Evaluation and Research. In that role she managed a $3 billion budget and led center operations, responsibilities the internal email highlighted as part of her qualifications for the incoming assignment.


Makary also announced a further change in the agencys operations leadership. Melissa Shea will become the FDAs principal deputy associate commissioner for operations and deputy chief operating officer, replacing Keller in that deputy role. Shea arrives with more than 24 years of experience in program management and business operations.

Before joining the FDA, Shea held senior positions at the Defense Health Agency, where she oversaw a contracting portfolio of more than $5.3 billion and managed the $26 billion TRICARE military health insurance program, according to the announcement.


The leadership changes at the FDA are taking place amid a broader reshuffling of top public health posts across federal agencies. The internal communication noted that last month the National Institutes of Health director Jay Bhattacharya was named acting director of the Centers for Disease Control and Prevention.

The memo framed the personnel moves at the CDC and elsewhere as following months of upheaval under Health and Human Services Secretary Robert F. Kennedy Jr., described in the memo as a longtime vaccine skeptic who has pushed aggressive changes across federal health agencies. That initiative has included the firing of former CDC Director Susan Monarez for resisting vaccine-policy changes and has triggered multiple senior resignations, the email said.

Agency officials are set to implement the outlined transitions on the stated timelines, with Keller taking over Butlers operational responsibilities on April 6 and Shea assuming the deputy operations role previously held by Keller.

Risks

  • Ongoing leadership turnover across federal public health agencies could create operational uncertainty within agencies charged with regulatory oversight - sectors impacted: healthcare, pharmaceuticals, public health administration.
  • Policy-driven personnel changes at the Department of Health and Human Services have led to firings and multiple senior resignations, which may disrupt continuity in public health programs and decision-making - sectors impacted: public health, disease control, regulatory affairs.
  • The memo describes a period of organizational upheaval tied to aggressive changes pushed by HHS leadership, indicating potential for further personnel shifts or restructuring that would affect agency operations - sectors impacted: federal health agencies and regulatory oversight.

More from Stock Markets

Broadcom Raises Q2 Outlook as AI-Driven Chip Orders Climb, Announces $10 Billion Buyback Mar 4, 2026 Palantir Must Strip Anthropic’s Claude From Pentagon AI Platform, Forcing Software Rebuild Mar 4, 2026 PepGen Shares Tumble After FDA Places Partial Hold on FREEDOM2-DM1 Trial Mar 4, 2026 After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva and more see volatile reactions Mar 4, 2026 Toronto market edges higher as IT, telecom and financials lead gains Mar 4, 2026